BioSpace News Archive

Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as chief operating officer

Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will participate at the following conferences

TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10 th at 5:00 PM ET – Company to report conclusions from its comprehensive strategic review, outline its updated business plan and report its fiscal year 2021 financial results

Dr. Stephen Palmer joins the Celmatix executive team to lead the company’s drug discovery and development efforts in ovarian health as Chief Scientific Officer

Verseau Therapeutics, Inc. today announced the appointment of John Edwards as Chief Executive Officer. John brings over 30 years of biopharmaceutical leadership experience and has been involved in the discovery, development or global commercialization of 10 FDA-approved biologics and eight biotech companies with successful exits.

Synexis today announced the appointment of Karin De Bondt to the Synexis board of directors, effective immediately.

Akili Interactive (“Akili” or “Company”), maker of EndeavorRx™, the first and only prescription video game treatment, today announced $160M in combined equity and debt financing.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the FDA plans to initiate its pre-approval inspection of the company’s manufacturing facility for DaxibotulinumtoxinA for Injection by the end of June 2021.

– Clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol – – Study conducted in collaboration with the Montreal Heart Institute and led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) – – Topline data readout expected Q4 2021

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the National Cancer Institute (NCI).